Targeting Multiple Kinase Pathways: A Change In Paradigm

被引：95

作者：

Gossage, Lucy ^{[1
,2
]}

Eisen, Tim ^{[2
,3
]}

机构：

[1] MRC, Ctr Prot Engn, Cambridge CB2 0QH, England

[2] CRUK Cambridge Res Inst, Cambridge, England

[3] Addenbrookes Hosp, Cambridge Biomed Res Ctr, Cambridge, England

来源：

CLINICAL CANCER RESEARCH | 2010年 / 16卷 / 07期

关键词：

RENAL-CELL CARCINOMA; PHASE-II TRIAL; LUNG-CANCER; COLORECTAL-CANCER; 1ST-LINE THERAPY; DOUBLE-BLIND; BEVACIZUMAB; ERLOTINIB; COMBINATION; EFFICACY;

D O I：

10.1158/1078-0432.CCR-09-3182

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Anticancer drugs that target protein kinases include small molecule inhibitors and monoclonal antibodies. Feedback loops and cross talk between signaling pathways impact significantly on the efficacy of cancer therapeutics, and resistance to targeted agents is a major barrier to effective treatments. Increasingly, therapies are being designed to target multiple kinase pathways. This can be achieved using a single agent that inhibits multiple signaling pathways or a combination of highly selective agents. In this review we discuss the principles of specifically targeting multiple kinase pathways with particular reference to angiogenic signaling pathways. Clin Cancer Res; 16(7); 1973-8. (C)2010 AACR.

引用

页码：1973 / 1978

页数：6

共 50 条

[1] KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience [J].

Bokemeyer, C. ;

Bondarenko, I. ;

Hartmann, J. T. ;

De Braud, F. G. ;

Volovat, C. ;

Nippgen, J. ;

Stroh, C. ;

Celik, I. ;

Koralewski, P. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

[2]

Bukowski RM, 2007, J CLIN ONCOL, V25, P4536, DOI 10.1200/JCO.2007.11.5154

[3]

Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/JCI34739, 10.1172/jCI34739]

[4] The role of VEGF receptors in angiogenesis;: complex partnerships [J].

Cébe-Suarez, S ;

Zehnder-Fjällman, A ;

Ballmer-Hofer, K .

CELLULAR AND MOLECULAR LIFE SCIENCES, 2006, 63 (05) :601-615

[5] Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study [J].

Cohen, Ezra E. W. ;

Davis, Darren W. ;

Karrison, Theodore G. ;

Seiwert, Tanguy Y. ;

Wong, Stuart J. ;

Nattam, Sreenivasa ;

Kozloff, Mark F. ;

Clark, Joseph I. ;

Yan, Duen-Hwa ;

Liu, Wen ;

Pierce, Carolyn ;

Dancey, Janet E. ;

Stenson, Kerstin ;

Blair, Elizabeth ;

Dekker, Allison ;

Vokes, Everett E. .

LANCET ONCOLOGY, 2009, 10 (03) :247-257

[6] Resistance to EGF-R (erbB-1) and VEGF-R modulating agents [J].

Dempke, Wolfram C. M. ;

Heinemann, Volker .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (07) :1117-1128

[7] A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer [J].

Dickler, Maura N. ;

Rugo, Hope S. ;

Eberle, CareyA. ;

Brog, Edi ;

Caravelli, James F. ;

Panageas, Katherine S. ;

Boyd, Jeff ;

Yeh, Benjamim ;

Lake, Diana E. ;

Dang, Chau T. ;

Gilewski, Teresa A. ;

Bromberg, Jacqueline F. ;

Seidman, Andrew D. ;

D'Andrea, Gabriella M. ;

Moasser, Mark M. ;

Melisko, Michele ;

Park, John W. ;

Dancey, Janet ;

Norton, Larry ;

Hudis, Clifford A. .

CLINICAL CANCER RESEARCH, 2008, 14 (23) :7878-7883

[8] Sequential Therapy With Sorafenib and Sunitinib in Renal Cell Carcinoma [J].

Dudek, Arkadiusz Z. ;

Zolnierek, Jakub ;

Dham, Anu ;

Lindgren, Bruce R. ;

Szczylik, Cezary .

CANCER, 2009, 115 (01) :61-67

[9] Phase II trial of the oral multikinase inhibitor BAY 73-4506 as 1st-line therapy in patients with metastatic or unresectable renal cell cancer (RCC) [J].

Eisen, T. ;

Joensuu, H. ;

Nathan, P. ;

Harper, P. ;

Wojtukiewicz, M. ;

Nicholson, S. ;

Bahl, A. ;

Tomczak, P. ;

Wagner, A. ;

Quinn, D. .

EJC SUPPLEMENTS, 2009, 7 (02) :424-424

[10] Targeting PI3K signalling in cancer: opportunities, challenges and limitations [J].

Engelman, Jeffrey A. .

NATURE REVIEWS CANCER, 2009, 9 (08) :550-562

← 1 2 3 4 5 →